NASDAQ:ZEAL Zealand Pharma A/S Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. $13.75 0.00 (0.00%) (As of 06/28/2022 12:00 AM ET) Add Compare Share Today's Range$13.75▼$13.7550-Day Range$10.05▼$14.3952-Week Range$9.93▼$34.30Volume164 shsAverage Volume960 shsMarket Capitalization$639.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ZEAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ZEAL Stock Forecast (MarketRank)Overall MarketRank™1.00 out of 5 starsMedical Sector1262nd out of 1,433 stocksPharmaceutical Preparations Industry621st out of 685 stocksAnalyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Zealand Pharma A/S. Previous Next 4.4 Community Rank Outperform VotesZealand Pharma A/S has received 289 “outperform” votes. (Add your “outperform” vote.)Underperform VotesZealand Pharma A/S has received 151 “underperform” votes. (Add your “underperform” vote.)Community SentimentZealand Pharma A/S has received 65.68% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Zealand Pharma A/S and other stocks. Vote “Outperform” if you believe ZEAL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ZEAL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldZealand Pharma A/S does not currently pay a dividend.Dividend GrowthZealand Pharma A/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zealand Pharma A/S insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 1.81% of the stock of Zealand Pharma A/S is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zealand Pharma A/S are expected to grow in the coming year, from ($3.53) to ($2.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zealand Pharma A/S is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zealand Pharma A/S is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZealand Pharma A/S has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zealand Pharma A/S (NASDAQ:ZEAL)Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.Read More ZEAL Stock News HeadlinesJune 3, 2022 | finance.yahoo.comZealand Pharma to Participate in Upcoming Investor ConferencesJune 2, 2022 | seekingalpha.comDr. David Kendall named Zealand Pharma CMOJune 2, 2022 | finance.yahoo.comZealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical OfficerMay 31, 2022 | finance.yahoo.comZealand Pharma Announces Multiple Presentations at the 82nd Annual American Diabetes Association Scientific Sessions, Including Initial Clinical Data on GLP-1/GLP-2 Dual Agonist DapiglutideMay 25, 2022 | finance.yahoo.comZealand Pharma launches long-term incentive program for Zealand’s Corporate Management and employees for 2022May 19, 2022 | investing.com"We Think There is a Good Chance of Broad-label Approval" - Needham & Company Bullish on Zealand Pharma Following Phase 3 DataMay 19, 2022 | marketwatch.comZealand Pharma Shares Rise 16% After Trial Results for DasiglucagonMay 19, 2022 | markets.businessinsider.comWhy Zealand Pharma Shares Are RisingMay 19, 2022 | msn.comZealand Pharma's Dasiglucagon Aces Late-Stage Study In Pediatric Patients, Shares Move HigherMay 19, 2022 | seekingalpha.comZealand Pharma stock soars 17% as dasiglucagon meets main goal in congenital hyperinsulinism study in infantsMay 19, 2022 | finance.yahoo.comZealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)May 19, 2022 | finance.yahoo.comZealand Pharma to seek FDA approval of its treatment for rare genetic disorder in babiesMay 17, 2022 | seekingalpha.comMannKind to acquire insulin delivery device V-Go from Zealand Pharma to bolster diabetes portfolioSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZEAL CUSIPN/A CIK1674988 Webwww.zealandpharma.com Phone(458) 877-3600Fax45-8877-3898Employees355Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today6/29/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Profitability EPS (Most Recent Fiscal Year)($3.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161.99 million Net Margins-380.22% Pretax Margin-364.34% Return on Equity-89.90% Return on Assets-50.80% Debt Debt-to-Equity Ratio0.93 Current Ratio4.79 Quick Ratio4.78 Sales & Book Value Annual Sales$46.54 million Price / Sales13.75 Cash FlowN/A Price / Cash FlowN/A Book Value$3.38 per share Price / Book4.07Miscellaneous Outstanding Shares46,530,000Free FloatN/AMarket Cap$639.79 million OptionableNot Optionable Beta1.37 Zealand Pharma A/S Frequently Asked Questions Should I buy or sell Zealand Pharma A/S stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Zealand Pharma A/S stock. View analyst ratings for Zealand Pharma A/S or view top-rated stocks. How has Zealand Pharma A/S's stock price performed in 2022? Zealand Pharma A/S's stock was trading at $21.34 at the beginning of 2022. Since then, ZEAL stock has decreased by 35.6% and is now trading at $13.75. View the best growth stocks for 2022 here. When is Zealand Pharma A/S's next earnings date? Zealand Pharma A/S is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Zealand Pharma A/S. How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (NASDAQ:ZEAL) issued its earnings results on Thursday, May, 12th. The company reported ($5.16) EPS for the quarter, topping the consensus estimate of ($6.61) by $1.45. Zealand Pharma A/S had a negative trailing twelve-month return on equity of 89.90% and a negative net margin of 380.22%. During the same period in the previous year, the firm earned ($0.94) earnings per share. View Zealand Pharma A/S's earnings history. Who are Zealand Pharma A/S's key executives? Zealand Pharma A/S's management team includes the following people: Mr. Adam Sinding Steensberg M.D., Pres & CEO (Age 48, Pay $729.62k)Mr. Matthew Donald Dallas, Sr. VP & CFO (Age 47, Pay $587.7k)Mr. Ivan Mourits Moller, Chief Operating Officer (Age 50)Lani Pollworth Morvan, Investor Relations & Communications OfficerMr. Mads Kronborg, Head of Investor Relations & CommunicationMr. Ravinder Chahil, Sr. VP & Gen. CounselMs. Christina Sonnenborg Bredal, Sr. VP and Global Head of People & Organization (Age 37)Ms. Hanne Heidenheim Bak, Sr. Project Director, R&D Operations Mang. and Employee Representative Director (Age 69)Dr. Jens Damsgaard Mikkelsen M.D., Head of Molecular PharmacologyDr. Danilo Verge, Head of Global Medical Affairs Who are some of Zealand Pharma A/S's key competitors? Some companies that are related to Zealand Pharma A/S include Insmed (INSM), Arvinas (ARVN), ACADIA Pharmaceuticals (ACAD), HUTCHMED (HCM), EQRx (EQRX), Global Blood Therapeutics (GBT), Schrödinger (SDGR), Sage Therapeutics (SAGE), ChemoCentryx (CCXI), Ironwood Pharmaceuticals (IRWD), Arcus Biosciences (RCUS), OPKO Health (OPK), Amphastar Pharmaceuticals (AMPH), Xenon Pharmaceuticals (XENE) and Lyell Immunopharma (LYEL). View all of ZEAL's competitors. What other stocks do shareholders of Zealand Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zealand Pharma A/S investors own include AbbVie (ABBV), Galapagos (GLPG), Verizon Communications (VZ), Dynavax Technologies (DVAX), EyePoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Protalix BioTherapeutics (PLX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE). When did Zealand Pharma A/S IPO? (ZEAL) raised $75 million in an initial public offering (IPO) on Wednesday, August 9th 2017. The company issued 3,900,000 shares at a price of $19.30 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. What is Zealand Pharma A/S's stock symbol? Zealand Pharma A/S trades on the NASDAQ under the ticker symbol "ZEAL." Who are Zealand Pharma A/S's major shareholders? Zealand Pharma A/S's stock is owned by many different institutional and retail investors. Top institutional shareholders include Farallon Capital Management LLC (1.14%) and Bank of America Corp DE (0.51%). Which major investors are selling Zealand Pharma A/S stock? ZEAL stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC. Which major investors are buying Zealand Pharma A/S stock? ZEAL stock was bought by a variety of institutional investors in the last quarter, including Bank of America Corp DE. How do I buy shares of Zealand Pharma A/S? Shares of ZEAL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zealand Pharma A/S's stock price today? One share of ZEAL stock can currently be purchased for approximately $13.75. How much money does Zealand Pharma A/S make? Zealand Pharma A/S (NASDAQ:ZEAL) has a market capitalization of $639.79 million and generates $46.54 million in revenue each year. The company earns $-161.99 million in net income (profit) each year or ($3.62) on an earnings per share basis. How many employees does Zealand Pharma A/S have? Zealand Pharma A/S employs 355 workers across the globe. How can I contact Zealand Pharma A/S? Zealand Pharma A/S's mailing address is SYDMARKEN 11, COPENHAGEN G7, 2860. The official website for Zealand Pharma A/S is www.zealandpharma.com. The company can be reached via phone at (458) 877-3600, via email at [email protected], or via fax at 45-8877-3898. This page (NASDAQ:ZEAL) was last updated on 6/29/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
